Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707058 | 0.81 | FKBP1A (0.36) | FKBP1ACYP1A2 | |
| SCHEMBL16516708 | 0.81 | ALDH1A1 (0.40) | FKBP1AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20930306 | 0.77 | ALDH1A1 (0.33) | FKBP1A | |
| SCHEMBL535757 | 0.75 | FKBP1A (0.36) | FKBP1AMAPK1 | |
| SCHEMBL7614074 | 0.74 | MAPK1 (0.45) | CYP1A2MAPK1 | |
| SCHEMBL2057726 | 0.74 | MMP3 (0.36) | FKBP1A | |
| SCHEMBL2058089 | 0.74 | MMP3 (0.36) | FKBP1A | |
| SCHEMBL2057725 | 0.74 | MMP3 (0.36) | FKBP1A | |
| SCHEMBL1005232 | 0.73 | MAPK1 (0.51) | CYP1A2MAPK1 | |
| SCHEMBL10567776 | 0.72 | FKBP1A (0.34) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| CN-112996785-A | Therapeutic compounds | 希四克斯探索有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | FKBP1A 928/4885HPGD 174/4885CYP1A2 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.